Published on April 2, 2021
Written by Peter Yim, trialsitenews.com
WHO updated “Therapeutics and COVID-19” on March 31, 2021 to include a recommendation on ivermectin. The recommendation was: NEGATIVE.
The recommendation was made by the Guideline Development Group; 63 members consisting of “content experts, clinicians, patients, ethicists and methodologists”.
“We recommend not to use ivermectin in patients with COVID-19 except in the context of a clinical trial.”
WHO explained that a vote on the recommendation was not necessary:
Two questions:“While a priori voting rules informed procedures if the panel failed to reach consensus, these procedures proved unnecessary for this recommendation.”
- Was there an “a priori” system in place for deciding when and how to abandon the “a priori” voting rules?
- How was consensus determined?
- Is it too late to take a vote?
WHO explained how they reached their “transparent and trustworthy recommendations”. They need to understand that bypassing a vote on the recommendation is the opposite of transparent and trustworthy.
Commenting on the above article, one reader, Andrew-PearceApril 2, 2021 lamented:
More at trialsitenews.com“Did you expect anything different? Any inexpensive, off-patent treatment, no matter how effective, must be beaten down and blackballed. Patient health and survival does not matter; massive profits for the research companies and the Big Pharm industry is the one and only goal. You’d have to be deaf, dumb, and blind not to accept this, after seeing it dozens of times over the past 16 months.”
Thanks to: https://principia-scientific.com